Eli Lilly Launches Foundayo Weight-Loss Pill in U.K., First European Market
LLY sits 81% above its 52-week low of $694.23.
Summary
Eli Lilly has launched its oral weight-loss drug Foundayo in the U.K., the first European market for the product. The once-daily pill is available via private prescription starting this week, with NHS coverage still under assessment. U.K. regulators approved Foundayo earlier this month for weight loss and type 2 diabetes. This follows the FDA approval noted in the Q2 10-Q and positions Lilly against Novo Nordisk's Wegovy pill, which launched in the U.K. in July and has already reached ~300,000 patients. The launch expands Foundayo's commercial footprint into a key European market and intensifies competition in the oral GLP-1 space.
At the time of this announcement, LLY was trading at $1,256.62 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.2T. The 52-week trading range was $694.23 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.